Ahmad Jawad Sabir

Ahmad Jawad Sabir

Auto-generated profile, based on publicly available information

Ahmad Jawad Sabir

Department of Microbiology and Immunology, University of Illinois Chicago, Chicago, IL, 60612, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Cell Insight
Verified
Journal Article
Open access
ASAhmad Jawad Sabir
Ahmad Jawad Sabir
Lijun RongLijun Rong
Lijun Rong
CBChristopher C. Broder
Christopher C. Broder
MAMoushimi Amaya
Moushimi Amaya
Nipah Virus (NiV) and Hendra Virus (HeV), are the prototype species of the genus Henipavirus and are highly pathogenic agents capable of causing fatal diseases in both animals and humans. Both NiV and HeV are classified as biosafety level-4 (BSL-4) restricted pathogens and remain the only henipaviruses within the genus known to cause systemic, severe respiratory and encephalitic henipaviral disease, and represent substantial transboundary threats. There are no approved prophylactic or therapeutic treatments for human henipavirus infections, and the World Health Organization acknowledges them as priority pathogens needing urgent research. The discovery of Cedar virus (CedV), the only recognized non-pathogenic henipavirus, has provided a number of unique opportunities to study henipavirus and host interactions and also facilitate countermeasure development research at lower BSL-2 containment. This review will highlight the unique aspects of CedV biology and how it has been exploited as a model for developing therapeutic strategies against more virulent henipavirus species.

17 February 2025 in Antiviral Research
Verified
Journal Article
Open access
Carolina SacramentoCarolina Sacramento
Carolina Sacramento
RBRyan Bott
Ryan Bott
QHQinfeng Huang
Qinfeng Huang
BEBrett Eaton
Brett Eaton
EPElena Postnikova
Elena Postnikova
Lijun RongLijun Rong
Lijun Rong
Several arenaviruses, such as the Old World (OW) Lassa virus (LASV) and the New World (NW) Junin virus (JUNV), can cause severe and lethal viral hemorrhagic fevers in humans. Currently, no vaccines or specific antiviral therapies are FDA-approved for treating arenavirus infections. One major challenge for the development of new therapeutic candidates against these highly pathogenic viruses is that they are BSL-3/4 pathogens that need to be handled in high biocontainment laboratories. In this work, a recombinant non-pathogenic New World arenavirus, Pichinde virus (rPICV), was used for the development of a high-throughput screening (HTS) assay in the BSL-2 laboratory for the screening and identification of small molecule inhibitors against arenaviruses. The rPICV is a replication-competent virus expressing the firefly luciferase reporter gene in the infected cells proportionally to the infection rate. rPICV infection was optimized for an automated HTS in 384-well format with robust Z' scores, high signal-to-background ratios, and low intrinsic variance. Screening an established library allowed for the identification of five top hit compounds, which included ribavirin, a known inhibitor of arenaviral RNA synthesis, showing good potency and selectivity in inhibiting rPICV replication. The antiviral activity of the top hit compounds was further validated against another recombinant arenavirus, the OW lymphocytic choriomeningitis virus (rLCMV) and against laboratory strains of LASV (Josiah) and JUNV (Romero). The use of rPICV in the HTS-based antiviral assay under BSL-2 condition has proven to be safe and suitable for the identification of broad-spectrum small molecule inhibitors against highly pathogenic arenaviruses.

20 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
Carolina SacramentoCarolina Sacramento
Carolina Sacramento
RBRyan Bott
Ryan Bott
QHQinfeng Huang
Qinfeng Huang
BEBrett Eaton
Brett Eaton
EPElena Postnikova
Elena Postnikova
Lijun RongLijun Rong
Lijun Rong
Several arenaviruses, such as the Old World (OW) Lassa virus (LASV) and the New World (NW) Junin virus (JUNV), can cause severe and lethal viral hemorrhagic fevers in humans. Currently, no vaccines or specific antiviral therapies are FDA-approved for treating arenavirus infections. One major challenge for the development of new therapeutic candidates against these highly pathogenic viruses is that they are BSL-3/4 pathogens that need to be handled in high biocontainment laboratories. In this work, a recombinant non-pathogenic New World arenavirus, Pichinde virus (rPICV), was used for the development of a high-throughput screening (HTS) assay in the BSL-2 laboratory for the screening and identification of small molecule inhibitors against arenaviruses. The rPICV is a replication-competent virus expressing the firefly luciferase reporter gene in the infected cells proportionally to the infection rate. rPICV infection was optimized for an automated HTS in 384-well format with robust Z′ scores, high signal-to-background ratios, and low intrinsic variance. Screening an established library allowed for the identification of five top hit compounds, which included ribavirin, a known inhibitor of arenaviral RNA synthesis, showing good potency and selectivity in inhibiting rPICV replication. The antiviral activity of the top hit compounds was further validated against another recombinant arenavirus, the OW lymphocytic choriomeningitis virus (rLCMV) and against laboratory strains of LASV (Josiah) and JUNV (Romero). The use of rPICV in the HTS-based antiviral assay under BSL-2 condition has proven to be safe and suitable for the identification of broad-spectrum small molecule inhibitors against highly pathogenic arenaviruses.